Amer Zeidan, MBBS, MHS, on the Evolution of AML Classification, Treatment
The HemOnc Pulse
00:00
IDH1 and Venetoclax in a Younger Patient Population
A lot of the clinical research offers are focusing on this patient population. Patients who have IDH1 and IDH2 who are younger, the standard of care is still 7 plus 3. We do not give these patients HMA. The reason for this is that we don't think we can cure people by giving HMA with an IDH inhibitor.
Transcript
Play full episode
